Skyrizi vs. Otezla

Are Skyrizi and Otezla the Same Thing?

Skyrizi (risankizumab-rzaa) and Otezla (apremilast) are used to treat different types of psoriasis.

Skyrizi is used to treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Otezla is used to treat adult patients with active psoriatic arthritis.

Skyrizi and Otezla belong to different drug classes. Skyrizi is an interleukin-23 antagonist and Otezla is a phosphodiesterase 4 (PDE4) inhibitor.

Side effects of Skyrizi and Otezla that are similar include upper respiratory infections, headache, and fatigue.

Side effects of Skyrizi that are different from Otezla include injection site reactions (bruising, redness, fluid leakage, bleeding, infection, inflammation, irritation, pain, itching, swelling, warmth) and tinea infections (such as ringworm, athlete's foot, and jock itch).

Side effects of Otezla that are different from Skyrizi include diarrhea, nausea, vomiting, runny or stuffy nose, abdominal pain, indigestion/heartburn, decreased appetite, insomnia, back pain, frequent bowel movements, depression, bronchitis, tooth abscess, sinus headache, weight loss, gastroesophageal reflux disease (GERD), migraine, cough, and rash.

Skyrizi may interact with "live" vaccines.

Otezla may interact with CYP450 inducers (such as rifampin, phenobarbital, carbamazepine, and phenytoin).

What Are Possible Side Effects of Skyrizi?

Side effects of Skyrizi include:

  • upper respiratory infections,
  • headache,
  • fatigue,
  • injection site reactions (bruising, redness, fluid leakage, bleeding, infection, inflammation, irritation, pain, itching, swelling, warmth), and
  • tinea infections (such as ringworm, athlete's foot and jock itch)

What Are Possible Side Effects of Otezla?

Common side effects of Otezla include:

  • diarrhea,
  • headache,
  • nausea,
  • upper respiratory tract infection,
  • vomiting,
  • runny or stuffy nose,
  • abdominal pain,
  • fatigue,
  • indigestion/heartburn,
  • decreased appetite,
  • insomnia,
  • back pain,
  • frequent bowel movements,
  • depression,
  • bronchitis,
  • tooth abscess, and
  • sinus headache.

What Is Skyrizi?

Skyrizi (risankizumab-rzaa) is an interleukin-23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

What Is Otezla?

Otezla (apremilast) is a phosphodiesterase 4 (PDE4) inhibitor used to treat adult patients with active psoriatic arthritis.

What Drugs Interact With Skyrizi?

Skyrizi may interact with "live" vaccines. Tell your doctor all medications and supplements you use and all vaccines you recently received. Tell your doctor if you are pregnant or plan to become pregnant before using Skyrizi; it is unknown how it would affect a fetus. It is unknown if Skyrizi passes into breast milk. Consult your doctor before breastfeeding.

What Drugs Interact With Otezla?

Otezla may interact with CYP450 inducers (such as rifampin).

How Should Skyrizi Be Taken?

The dose of Skyrizi is 150 mg (two 75 mg injections) administered by subcutaneous injection at Week 0, Week 4 and every 12 weeks thereafter.

How Should Otezla Be Taken?

The recommended maintenance dosage is 30 mg twice daily taken orally starting on Day 6, after 5 days of an initial schedule of titration dosing.

Disclaimer

All drug information provided on RxList.com is sourced directly from drug monographs published by the U.S. Food and Drug Administration (FDA).

Any drug information published on RxList.com regarding general drug information, drug side effects, drug usage, dosage, and more are sourced from the original drug documentation found in its FDA drug monograph.

Drug information found in the drug comparisons published on RxList.com is primarily sourced from the FDA drug information. The drug comparison information found in this article does not contain any data from clinical trials with human participants or animals performed by any of the drug manufacturers comparing the drugs.

The drug comparisons information provided does not cover every potential use, warning, drug interaction, side effect, or adverse or allergic reaction. RxList.com assumes no responsibility for any healthcare administered to a person based on the information found on this site.

As drug information can and will change at any time, RxList.com makes every effort to update its drug information. Due to the time-sensitive nature of drug information, RxList.com makes no guarantees that the information provided is the most current.

Any missing drug warnings or information does not in any way guarantee the safety, effectiveness, or the lack of adverse effects of any drug. The drug information provided is intended for reference only and should not be used as a substitute for medical advice.

If you have specific questions regarding a drug’s safety, side effects, usage, warnings, etc., you should contact your doctor or pharmacist, or refer to the individual drug monograph details found on the FDA.gov or RxList.com websites for more information.

You may also report negative side effects of prescription drugs to the FDA by visiting the FDA MedWatch website or calling 1-800-FDA-1088.

References
SOURCE:

AbbVie Inc. Skyrizi Product Information.
https://www.skyrizi.com
Abbvie. Humira Product Monograph.
https://www.humira.com/